Literature DB >> 17190598

ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.

Yung C Lam1, Aaron B Bowman, Paymaan Jafar-Nejad, Janghoo Lim, Ronald Richman, John D Fryer, Eric D Hyun, Lisa A Duvick, Harry T Orr, Juan Botas, Huda Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative diseases caused by expansion of a polyglutamine tract in the disease protein, in this case, ATAXIN-1 (ATXN1). A key question in the field is whether neurotoxicity is mediated by aberrant, novel interactions with the expanded protein or whether its wild-type functions are augmented to a deleterious degree. We examined soluble protein complexes from mouse cerebellum and found that the majority of wild-type and expanded ATXN1 assembles into large stable complexes containing the transcriptional repressor Capicua. ATXN1 directly binds Capicua and modulates Capicua repressor activity in Drosophila and mammalian cells, and its loss decreases the steady-state level of Capicua. Interestingly, the S776A mutation, which abrogates the neurotoxicity of expanded ATXN1, substantially reduces the association of mutant ATXN1 with Capicua in vivo. These data provide insight into the function of ATXN1 and suggest that SCA1 neuropathology depends on native, not novel, protein interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17190598     DOI: 10.1016/j.cell.2006.11.038

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  168 in total

Review 1.  Nuclear ataxias.

Authors:  Harry T Orr
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

2.  Suppression of the novel ER protein Maxer by mutant ataxin-1 in Bergman glia contributes to non-cell-autonomous toxicity.

Authors:  Hiroki Shiwaku; Natsue Yoshimura; Takuya Tamura; Masaki Sone; Soichi Ogishima; Kei Watase; Kazuhiko Tagawa; Hitoshi Okazawa
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

Review 3.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

Review 4.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 5.  Polyglutamine neurodegeneration: expanded glutamines enhance native functions.

Authors:  Harry T Orr
Journal:  Curr Opin Genet Dev       Date:  2012-01-25       Impact factor: 5.578

6.  Gcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model.

Authors:  Yi Chun Chen; Jennifer R Gatchel; Rebecca W Lewis; Chai-An Mao; Patrick A Grant; Huda Y Zoghbi; Sharon Y R Dent
Journal:  Hum Mol Genet       Date:  2011-10-14       Impact factor: 6.150

Review 7.  SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.

Authors:  Harry T Orr
Journal:  Prog Neurobiol       Date:  2012-04-16       Impact factor: 11.685

8.  Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity.

Authors:  Eriko Suzuki; Yue Zhao; Saya Ito; Shun Sawatsubashi; Takuya Murata; Takashi Furutani; Yuko Shirode; Kaoru Yamagata; Masahiko Tanabe; Shuhei Kimura; Takashi Ueda; Sally Fujiyama; Jinseon Lim; Hiroyuki Matsukawa; Alexander P Kouzmenko; Toshiro Aigaki; Tetsuya Tabata; Ken-ichi Takeyama; Shigeaki Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 9.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

10.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.